Close menu




December 15th, 2020 | 15:37 CET

Moderna, AdTiger, AstraZeneca - here we go!

  • Investments
Photo credits: pixabay.com

The announcement of the second lockdown last Sunday is a disaster for brick-and-mortar retailers. After an extremely sluggish Christmas season so far, the new closures will turn off the lights for stores during the most critical time of the year. Of the total 560,000 jobs in downtown retail, up to 250,000 are said to be acutely threatened. The beneficiary of this disastrous situation is once again, eCommerce. However, in addition to the major platforms Amazon, Alibaba or Zalando, other Internet companies are also profiting from the online trend.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: KYG009701064 , US60770K1079 , GB0009895292

Table of contents:


    AdTiger - Digital market booming

    Advertising is placed where the customer is. Due to the Corona pandemic and the recurring lockdowns, more and more people migrated away from the offline to the online marketplace. As a result, eCommerce sales worldwide are expected to grow between 15% and 20% this year. Advertising platforms are responsible for ensuring that the customer sees the right things, personalized just for him, in the banners or displays. One of the interesting players is the Chinese advertising platform AdTiger. AdTiger's primary goal is to connect Chinese advertisers who operate internationally with the biggest social media platforms and apps, mainly from the US.

    Partnerships with the big players

    The Chinese partners read like the crème de la crème of the social media industry. For example, AdTiger is a China Export Partner (CEP) of Facebook and ranked first among Facebook's 23 CEP's in terms of ad spend on Facebook's ad inventory in 2019, and also has an agreement with Google in the AdWords Reseller Program. With Baidu, AdTiger is an authorized Snapchat sales representative. Direct cooperations are also in place with Yahoo and the emerging platform TikTok. Thus, there is enormous potential for the Chinese to direct their customers to all relevant channels.

    Expansion of Big Data and Artificial Intelligence

    To target advertising correctly, AdTiger uses its own specially programmed software, AdTensor. The program uses artificial intelligence to perform ad optimization and ad management automatically, intelligently, and in real-time. AdTensor's Big Data and AI capabilities make it possible to achieve optimal advertising goals for advertisers. It also helps to leverage the monetization potential of media publishers. Analysis and tracking in the field of artificial intelligence are to be expanded further. For example, AdTiger plans to make a significant addition to its Big Data team this year. The Company's shares have recently been trading at a current price of EUR 0.13 on the Frankfurt Stock Exchange. The market capitalization is currently just under EUR 80.0 million.

    AstraZeneca - Record deal in the bag

    To expand its business with drugs for rare diseases, AstraZeneca is prepared to put the internal record sum of USD 39 billion on the table for the US biotech Company Alexion. For the acquisition, AstraZeneca plans to pay USD 175 per Alexion share in cash as well as in its securities. The British pharmaceutical Company hopes that this will generate synergies of USD 500 million per year from the end of the third year of the takeover. Above all, profits are expected to bubble up. Double-digit percentage growth in core earnings per share is expected in the first three years after completion of the transaction.

    Analysts sceptical

    Analysts are less optimistic than the Company itself about the largest acquisition in the Company's history. According to Goldman Sachs, while the proposed deal improves cash inflow dynamics and provides a reasonable degree of diversification, the experts see a risk of diluted and potentially lower organic growth. Investors also took the news negatively, at least in the short term. The share opened with a minus of over 9% but was able to halve the losses in the course of trading.

    Moderna - Start in the USA

    What is currently still having a negative impact on the share price is the uncertain forecast as to when the British will submit an application for approval of their vaccine. Here, the competitors BioNTech and Pfizer, as well as the US Company Moderna, are months ahead. After an emergency approval by the health authority FDA, the delivery of the Corona vaccine of the Mainz-based pharmaceutical Company BioNTech and its US partner Pfizer is underway in the United States. Freight company FedEx said Sunday that its subsidiary FedEx Express would begin transporting the vaccine, which is frozen with dry ice.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by André Will-Laudien on January 31st, 2023 | 14:50 CET

    E-mobility 2023: The Tesla hunters are coming! BYD, Lucid Motors, Tocvan Ventures. Will the Varta share now also fly?

    • Mining
    • Gold
    • Electromobility
    • Investments

    It Is hard to believe! The Tesla share is once again making a name for itself. Analysts went into the presentation of the annual figures with cautious expectations because there were many negative rumors surrounding Elon Musk's electronics company: Fewer sales? Cars on stockpile? Again, it came as no one had expected it. Elon Musk delivered and simultaneously mocked all the shorties who wanted to push his stock below USD 100 at the turn of the year. This gambit went badly wrong because Tesla was able to deliver even better figures than expected, and there was no stopping the share. With plus 70% in only 4 weeks, the Tesla share belongs to the shooting stars since the turn of the year - the short sellers must have lost their desire completely. But the variety of interesting shares is significant. Where are the opportunities for e-investors lurking?

    Read

    Commented by Nico Popp on January 31st, 2023 | 14:33 CET

    This new project changes everything: Deutsche Bank, Aspermont, Alibaba

    • Digitization
    • Innovations
    • Technology
    • Investments

    When processes go digital, great opportunities arise: automation and scaling can ensure growth and turn established business models into high-flyers. But which companies should investors actively support in their transformation? Where is there real potential for investors, and where are companies just spreading buzzwords? We highlight three stocks for you.

    Read

    Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

    Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

    • Biotechnology
    • Cancer
    • Covid19
    • Investments

    Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

    Read